Patents Assigned to Aulos Bioscience, Inc
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20240092888
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: October 23, 2023
    Publication date: March 21, 2024
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20230203152
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: November 16, 2022
    Publication date: June 29, 2023
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20230085471
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: February 15, 2021
    Publication date: March 16, 2023
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN